Cargando…
The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle?
Influenza is a serious respiratory disease responsible for significant morbidity and mortality due to both annual epidemics and pandemics; its treatment involves the use of neuraminidase inhibitors. (−)-Oseltamivir phosphate (Tamiflu) approved in 1999, is one of the most potent oral anti-influenza n...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382934/ https://www.ncbi.nlm.nih.gov/pubmed/32839628 http://dx.doi.org/10.1016/j.tet.2020.131440 |
_version_ | 1783563347682131968 |
---|---|
author | Sagandira, Cloudius R. Mathe, Francis M. Guyo, Upenyu Watts, Paul |
author_facet | Sagandira, Cloudius R. Mathe, Francis M. Guyo, Upenyu Watts, Paul |
author_sort | Sagandira, Cloudius R. |
collection | PubMed |
description | Influenza is a serious respiratory disease responsible for significant morbidity and mortality due to both annual epidemics and pandemics; its treatment involves the use of neuraminidase inhibitors. (−)-Oseltamivir phosphate (Tamiflu) approved in 1999, is one of the most potent oral anti-influenza neuraminidase inhibitors. Consequently, more than 70 Tamiflu synthetic procedures have been developed to date. Herein, we highlight the evolution of Tamiflu synthesis since its discovery over 20 years ago in the quest for a truly efficient, safe, cost-effective and environmentally benign synthetic procedure. We have selected a few representative routes to give a clear account of the past, present and the future with the advent of enabling technologies. |
format | Online Article Text |
id | pubmed-7382934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73829342020-07-28 The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle? Sagandira, Cloudius R. Mathe, Francis M. Guyo, Upenyu Watts, Paul Tetrahedron Tetrahedron Report 1211 Influenza is a serious respiratory disease responsible for significant morbidity and mortality due to both annual epidemics and pandemics; its treatment involves the use of neuraminidase inhibitors. (−)-Oseltamivir phosphate (Tamiflu) approved in 1999, is one of the most potent oral anti-influenza neuraminidase inhibitors. Consequently, more than 70 Tamiflu synthetic procedures have been developed to date. Herein, we highlight the evolution of Tamiflu synthesis since its discovery over 20 years ago in the quest for a truly efficient, safe, cost-effective and environmentally benign synthetic procedure. We have selected a few representative routes to give a clear account of the past, present and the future with the advent of enabling technologies. Elsevier Ltd. 2020-09-11 2020-07-26 /pmc/articles/PMC7382934/ /pubmed/32839628 http://dx.doi.org/10.1016/j.tet.2020.131440 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Tetrahedron Report 1211 Sagandira, Cloudius R. Mathe, Francis M. Guyo, Upenyu Watts, Paul The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle? |
title | The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle? |
title_full | The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle? |
title_fullStr | The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle? |
title_full_unstemmed | The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle? |
title_short | The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle? |
title_sort | evolution of tamiflu synthesis, 20 years on: advent of enabling technologies the last piece of the puzzle? |
topic | Tetrahedron Report 1211 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382934/ https://www.ncbi.nlm.nih.gov/pubmed/32839628 http://dx.doi.org/10.1016/j.tet.2020.131440 |
work_keys_str_mv | AT sagandiracloudiusr theevolutionoftamiflusynthesis20yearsonadventofenablingtechnologiesthelastpieceofthepuzzle AT mathefrancism theevolutionoftamiflusynthesis20yearsonadventofenablingtechnologiesthelastpieceofthepuzzle AT guyoupenyu theevolutionoftamiflusynthesis20yearsonadventofenablingtechnologiesthelastpieceofthepuzzle AT wattspaul theevolutionoftamiflusynthesis20yearsonadventofenablingtechnologiesthelastpieceofthepuzzle AT sagandiracloudiusr evolutionoftamiflusynthesis20yearsonadventofenablingtechnologiesthelastpieceofthepuzzle AT mathefrancism evolutionoftamiflusynthesis20yearsonadventofenablingtechnologiesthelastpieceofthepuzzle AT guyoupenyu evolutionoftamiflusynthesis20yearsonadventofenablingtechnologiesthelastpieceofthepuzzle AT wattspaul evolutionoftamiflusynthesis20yearsonadventofenablingtechnologiesthelastpieceofthepuzzle |